Stock ITCI INTRA-CELLULAR THERAPIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Real-time Estimate Cboe BZX
Other stock markets
 11:14:25 2024-04-16 am EDT 		5-day change 1st Jan Change
82.86 USD +27.94% Intraday chart for Intra-Cellular Therapies, Inc. +17.70% +12.77%
01:00pm Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder CI
Mar. 19 Intra-Cellular Therapies CFO Hineline Retiring, Promotes Halstead to President MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Intra-Cellular Therapies, Inc. - Special Call
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
AQ
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
CI
Intra-Cellular Therapies CFO Hineline Retiring, Promotes Halstead to President
MT
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
AQ
Intra-Cellular Therapies, Inc. Announces Executive Changes
CI
Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer
CI
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
AQ
Intra-Cellular Therapies Insider Sold Shares Worth $1,458,650, According to a Recent SEC Filing
MT
Intra-Cellular Therapies Insider Sold Shares Worth $1,808,253, According to a Recent SEC Filing
MT
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
AQ
Needham Adjusts Intra-Cellular Therapies Price Target to $82 From $72, Maintains Buy Rating
MT
Transcript : Intra-Cellular Therapies, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Intra-Cellular Therapies Q4 Loss Narrows, Revenue Increases
MT
Intra-Cellular: Q4 Earnings Snapshot
AQ
Intra-Cellular Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q4 Revenue $132.1M
MT
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
AQ
Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024
CI
Intra-Cellular Therapies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ITCI Stock
  4. News Intra-Cellular Therapies, Inc.